Fig. 2: Inhibitor binding to the active site of CatL.
From: Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections
a Domain structure of CatL with Calpeptin derived from prodrug S-Calpeptin bound to the active site. b Close-up view of the active site of CatL with bound S-Calpeptin. Residues involved in the catalytic mechanism are highlighted in stick representation. c Surface representation of the empty active site of CatL with the catalytic cysteine highlighted in yellow. Calpeptin derived from S-Calpeptin (d) and the GC-376 aldehyde (e) bound to the CatL active site with highlighted subsites S1–S3.
